The various therapeutic applications of the medical isotope holmium-166: a narrative review

Nienke J. M. Klaassen†, Mark J. Arntz†, Alexandra Gil Arranja1,2,3†, Joey Roosen† and J. Frank W. Nijsen†*†

* Correspondence: frank.nijsen@radboudumc.nl
† Nienke J. M. Klaassen, Mark J. Arntz, Alexandra Gil Arranja, Joey Roosen and J. Frank W. Nijsen contributed equally to this work.
1Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Radboud Institute for Health Sciences, Geert Grooteplein Zuid 10, 6525, GA, Nijmegen, The Netherlands
Full list of author information is available at the end of the article

Abstract
Over the years, a broad spectrum of applications of the radionuclide holmium-166 as a medical isotope has been established. The isotope holmium-166 is attractive as it emits high-energy beta radiation which can be used for a therapeutic effect and gamma radiation which can be used for nuclear imaging purposes. Furthermore, holmium-165 can be visualized by MRI because of its paramagnetic properties and by CT because of its high density. Since holmium-165 has a natural abundance of 100%, the only by-product is metastable holmium-166 and no costly chemical purification steps are necessary for production of nuclear reactor derived holmium-166. Several compounds labelled with holmium-166 are now used in patients, such Ho166-labelled microspheres for liver malignancies, Ho166-labelled chitosan for hepatocellular carcinoma (HCC) and [166Ho]Ho DOTMP for bone metastases. The outcomes in patients are very promising, making this isotope more and more interesting for applications in interventional oncology. Both drugs as well as medical devices labelled with radioactive holmium are used for internal radiotherapy. One of the treatment possibilities is direct intratumoural treatment, in which the radioactive compound is injected with a needle directly into the tumour. Numerous other applications have been developed, like patches for treatment of skin cancer and holmium labelled antibodies and peptides. The second major application that is currently clinically applied is selective internal radiation therapy (SIRT, also called radioembolization), a novel treatment option for liver malignancies. This review discusses medical drugs and medical devices based on the therapeutic radionuclide holmium-166.

Keywords: Holmium-166, Holmium, Lanthanide, Radiation therapy, SIRT, Microspheres, Chitosan, DOTMP

Introduction
Holmium is one of the 15 rare earth elements called lanthanides, a group of elements that has become an established source of radionuclides for nuclear diagnostic and therapeutic applications (Nayak and Lahiri 1999). Holmium-166 (166Ho) can be produced by two methods; neutron activation by (n, γ) irradiation in a nuclear reactor (Nayak and Lahiri 1999; Nijsen et al. 1999) or by neutron activation of dysprosium-164 (164Dy) (Nijsen et al. 2007) (Fig. 1). Because holmium-165 (165Ho) has a natural abundance of 100% and a cross section of 64 b (Foote Jr et al. 1953), it can be neutron activated in a relatively short neutron activation time resulting in 166Ho with a high purity.
of the isotope (Nijsen et al. 1999). The only by-product is metastable holmium-166 (\(^{166m}\)Ho), approximately a factor 7 \times 10^6 times less than \(^{166}\)Ho. \(^{166m}\)Ho has a half-life of 1200 years and emits beta radiation and a number of gamma rays between 80 and 1563 keV (Nijsen et al. 2007; Hino et al. 2000; Bernardes 2001). The cross section of the \(^{165}\)Ho(n, \(\gamma\))\(^{166}\)Ho reaction is 64 barns (Foote Jr et al. 1953) and the cross section of the \(^{165}\)Ho(n, \(\gamma\))\(^{166m}\)Ho reaction is around 3.4 barns for thermal neutrons (Nethaway and Missimer 1968).

The other production option is via neutron activation of \(^{164}\)Dy by two neutrons following a \((2n, \gamma)\) reaction forming dysprosium-166 (\(^{166}\)Dy). Dysprosium-164 has a natural abundance of 28.2% and enriched material will have a purity of over 90%. By capture of two neutrons, \(^{164}\)Dy will be converted into \(^{166}\)Dy which will decay into carrier-free \(^{166}\)Ho as the daughter radionuclide (\(^{166}\)Dy/\(^{166}\)Ho generator) (data were collected from the International Atomic Energy Agency Database: https://www-nds.iaea.org/).

As the half-life of \(^{166}\)Ho is 26.8 h, over 90% of the radiation is deposited in less than 4 days. The maximum tissue range of the beta particles in soft tissue is 8.7 mm, the average range 2.2 mm and 90% of the total radiation dose will be delivered in the first 2.1 mm (Johnson and Yanch 1991). This results in an interesting relatively high dose-rate if the

---

**Fig. 1** Diagrams of the production methods of (1) \(^{166}\)Ho and (2) \(^{166}\)Dy. Reactor neutron activated \(^{165}\)Ho will result in \(^{166}\)Ho with a high purity (1). The second method is via neutron activation of \(^{164}\)Dy by two neutrons. Dysprosium-164 has a natural abundance of 28.2% and enriched material will have a purity of over 90%. By capture of two neutrons, \(^{164}\)Dy will be converted into \(^{166}\)Dy which will decay into carrier-free \(^{166}\)Ho as the daughter radionuclide (\(^{166}\)Dy/\(^{166}\)Ho generator) (data were collected from the International Atomic Energy Agency Database: https://www-nds.iaea.org/).
same cumulative dose is given compared to other often used radioisotopes for cancer
treatment, such as phosphor-32 ($^{32}$P), yttrium-90 ($^{90}$Y), iodine-131 ($^{131}$I), lutetium-177
($^{177}$Lu) and rhenium-186 ($^{186}$Re), with half-lives between 2.7 and 14.3 days.

Over the last 30 years, 150 articles have been published on the use of $^{166}$Ho as a medical
isotope. Especially since the start of this century interest in this radioisotope has been
growing, resulting in around 6 publications per year (Fig. 2) and translated into the
development of many systems loaded or conjugated to holmium (Table 1). Since the
production of $^{166}$Ho has become more and more standardized, the number of clinical
applications (Fig. 3) and clinical trials (Table 2) has been growing and several compounds
are now used in patients: $^{166}$Ho-labelled microspheres for liver malignancies (Smits et al.
2012; Prince et al. 2018), $^{166}$Ho-labelled chitosan for hepatocellular carcinoma (HCC)
(Sohn et al. 2009) and $^{[166}$Ho]Ho DOTMP (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetra-
methylene-phosphonic acid) for bone metastases (Denis-Bacelar et al. 2018). Thus, it can
be expected that the significance of the use of this radioisotope will continue to grow
rapidly. In this review, the many therapeutic applications of $^{166}$Ho that have been
developed over the years are discussed.

Intratumoural applications

Chitosan

The medical isotope $^{166}$Ho is gaining more and more interest from nuclear physicians
in the treatment of tumours. Both drugs and medical devices labelled with radioactive
$^{166}$Ho are used for internal radiotherapy. One of the therapy possibilities is the direct
intratumoural treatment, in which the radioactive compound is injected with a needle
directly into the tumour (Fig. 3). Such an intratumoural application can be found in for
instance the $^{166}$Ho-labelled chitosan complex, which has been studied in different types
of tumours such as brain (Ha et al. 2013; Huh et al. 2005), liver (Sohn et al. 2009; Kim
et al. 2006) and prostate cancer (Kwak et al. 2005). Chitosan is a polymer obtained
from the deacetylation of chitin which can form chelates with heavy metals (Suzuki et

---

**Fig. 2** Number of $^{166}$Ho related publications over the years (search through PubMed)
Table 1 Representative examples of carriers that have been loaded or conjugated to holmium and to the dysprosium/holmium generator

| Bone seeking agents | DOTMP | (Bayouth et al. 1995a; Bayouth et al. 1995b; Parks et al. 1993; Giralt et al. 2003; Breitz et al. 2006; Rajendran et al. 2002; Ueno et al. 2009; Breitz et al. 2003a) |
|---------------------|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| EDTMP               | (Sohaib et al. 2011; Bahrami-Samani et al. 2010; Appelbaum et al. 1992; Louw et al. 1996) |                                                                                                                                                                                                     |
| PAM                 | (Vaez-Tehrani et al. 2016)                                                                                                                          |                                                                                                                                                                                                     |
| TTHMP               | (Yousefnia et al. 2014)                                                                                                                           |                                                                                                                                                                                                     |
| APDDMP              | (Marques et al. 2006; Zeevaart et al. 2001)                                                                                                      |                                                                                                                                                                                                     |
| Antibodies          | DO3A-4B4 | (Ballard et al. 2011)                                                                                                                                                                               |                                                                                                                                                                                                     |
|                     | CHX-A"DTPA-6D2 | (Thompson et al. 2014)                                                                                                                                                                             |                                                                                                                                                                                                     |
|                     | DOTA-CC49 | (Mohan et al. 2006; Mohsin et al. 2011)                                                                                                      |                                                                                                                                                                                                     |
|                     | MeO-DOTA-CC49 | (Mohsin et al. 2006; Mohsin et al. 2011)                                                                                                                                                            |                                                                                                                                                                                                     |
| Other complexes     | DTPA   | (Majali et al. 2001; Hong et al. 2002)                                                                                                                                                              |                                                                                                                                                                                                     |
|                     | DOTA    | (Das et al. 2003)                                                                                                                                                                                  |                                                                                                                                                                                                     |
|                     | Chitosan | (Ha et al. 2013; Huh et al. 2005; Kim et al. 2006; Kwak et al. 2005; Suzuki et al. 1998; Lee et al. 2006; Cho et al. 2010; Song et al. 2001; Lee et al. 2003) |                                                                                                                                                                                                     |
|                     | Oxine lipiodol | (Das et al. 2009b)                                                                                                                                                                                |                                                                                                                                                                                                     |
|                     | PMMA    | (Hirsch et al. 2008)                                                                                                                                                                               |                                                                                                                                                                                                     |
| Microparticles      | Glass   | (Costa et al. 2009; Brown et al. 1991)                                                                                                                                                              |                                                                                                                                                                                                     |
|                     | Resin   | (Turner et al. 1994; Subramanian et al. 2018; Costa and Osso Junior 2008)                                                                                                                          |                                                                                                                                                                                                     |
|                     | Alginate | (Zielhuis et al. 2007)                                                                                                                                                                             |                                                                                                                                                                                                     |
|                     | Lipiodol-alginate | (Orlemans et al. 2015)                                                                                                                                                                             |                                                                                                                                                                                                     |
|                     | AcAc-PLLA | (Nijsen et al. 1999; Mumper et al. 1992)                                                                                                                                                            |                                                                                                                                                                                                     |
|                     | Polyester | (Mumper and Jay 1992)                                                                                                                                                                              |                                                                                                                                                                                                     |
|                     | AcAc    | (Bult et al. 2012; Bult et al. 2009)                                                                                                                                                               |                                                                                                                                                                                                     |
|                     | PO₄     | (Bult et al. 2012; Arranja et al. 2018)                                                                                                                                                              |                                                                                                                                                                                                     |
|                     | Hydroxipatite | (Das et al. 2009a; Unni et al. 2002)                                                                                                      |                                                                                                                                                                                                     |
|                     | Ferric hydroxide (FHMA) | (Makela et al. 2004; Makela et al. 2003b; Vuorela et al. 2005; Kraft et al. 2007; Cho et al. 2010; Makela et al. 2004; Offuoglu et al. 2002) |                                                                                                                                                                                                     |
| Nanoparticles       | Mesoroporous silica nanoparticles | (Di Pasqua et al. 2013)                                                                                                                                                                          |                                                                                                                                                                                                     |
|                     | Mesoroporous carbon nanoparticles | (Kim et al. 2017)                                                                                                                                                                                 |                                                                                                                                                                                                     |
|                     | AcAc-DSPE-PEG | (Di Pasqua et al. 2012)                                                                                                                                                                           |                                                                                                                                                                                                     |
|                     | AcAc-PLLA | (Hamoudieh et al. 2008)                                                                                                                                                                              |                                                                                                                                                                                                     |
|                     | AcAc    | (Bult et al. 2010)                                                                                                                                                                                  |                                                                                                                                                                                                     |
| Liposomes           | DPPC-CholPEG-DSPE | (Zielhuis et al. 2006)                                                                                                                                                                         |                                                                                                                                                                                                     |
| Patches             | Tape    | (Lee et al. 1997; Chung et al. 2000)                                                                                                                                                               |                                                                                                                                                                                                     |
| Nanofibers          |         | (Munaweera et al. 2014)                                                                                                                                                                              |                                                                                                                                                                                                     |
| Ceramic materials   | Seeds   | (Diniz et al. 2017; Valente et al. 2011; Nogueira and Campos 2011; Nogueira and de Campos 2012; Nogueira and Campos 2016; Hosseini et al. 2013; Valente and Campos 2010; Won et al. 2005) |                                                                                                                                                                                                     |
|                     | Membranes | (Nogueira and de Campos 2012)                                                                                                                                                                       |                                                                                                                                                                                                     |
| Generator           | DTPA complex | (Smith et al. 1995)                                                                                                                                                                                |                                                                                                                                                                                                     |
|                     | Macroaggregates | (Makela et al. 2003a; Park et al. 1996; McLaren et al. 1990; Sledge et al. 1977)                                                                                               |                                                                                                                                                                                                     |
|                     | DTPA-Biotin | (Ferro-Flores et al. 2004; Ferro-Flores et al. 2003)                                                                                                                                               |                                                                                                                                                                                                     |
|                     | EDTMP    | (Pedraza-Lopez et al. 2004a)                                                                                                                                                                         |                                                                                                                                                                                                     |
al. 1998; Park 1997). Its solubility in water is pH-dependent. Below pH 4.0, it is readily soluble in water. However, under neutral or basic conditions, it is converted into a gelatinized material enabling the retention of the complex at the administration site. The $^{166}$Ho-labelled chitosan complex was developed as a radiopharmaceutical for cancer therapy by the Korean Atomic Energy Research Institute. Preparation of this complex for injection involves vigorously mixing a solution composed of $^{166}$Ho nitrate and chitosan for 2 to 3 min (Sohn et al. 2009; Kim et al. 2006; Kwak et al. 2005). A retention of $^{166}$Ho at the injection site of around 90% has been demonstrated using the $^{166}$Ho-labelled chitosan complex due to the formation of a gel in the microenvironment of the injection site (Kwak et al. 2005; Suzuki et al. 1998; Park 1997; Muzzarelli et al. 1988). In animal studies, it was shown that a significant decrease in tumour volume was measured in the treated group compared to the control group (Huh et al. 2005; Kwak et al. 2005; Suzuki et al. 1998). In clinical research, positive effects have been observed as well: Kim et al. demonstrated complete tumour necrosis in 80.8% (42 of 52) of the patients with small hepatocellular carcinoma (Kim et al. 2006). In a study of Ha et al., 70% of the patients with recurrent cystic brain tumours responded positively to treatment with $^{166}$Ho-labelled chitosan, without systematic absorption or leakage (Ha et al. 2013; Huh et al. 2005).

$^{166}$Ho-labelled chitosan has also been studied in order to treat renal cysts. Seventeen patients with renal cysts were injected with $^{166}$Ho-labelled chitosan under ultrasonographic guidance. At the end of the follow-up, 90% of the treated cysts had underwent a complete or near complete regression (Kim et al. 2004).

Table 1 Representative examples of carriers that have been loaded or conjugated to holmium and to the dysprosium/holmium generator (Continued)

| MOFDOTMP         | (Vosoghi et al. 2016) |
|------------------|-----------------------|
| Chitosan microspheres | (Cho and Choi 2018)  |

Fig. 3 Schematic overview of medical applications of the isotope $^{166}$Ho
Table 2: Clinical studies published at www.clinicaltrials.gov in which a compound with holmium-166 is used

| Study title                                                                 | Device/ drug | Tumour type                        | Compound                           | Sponsor                                                      | Time path               | ClinicalTrials.gov Identifier | Reference(s) |
|---------------------------------------------------------------------------|--------------|------------------------------------|------------------------------------|--------------------------------------------------------------|-------------------------|-------------------------------|---------------|
| QuiremSpheres Observational Study                                         | device       | Liver cancer, non-resectable tumors | Holmium-166 polylactic microspheres | Terumo Europe N.V.                                           | 2018 - (recruiting)     | NCT03563274                   |               |
| Holmium Radioembolization as Adjuvant Treatment to RFA for Early Stage HCC Radioembolization Study | device       | hepatocellular carcinoma           | RFA + Holmium-166 polylactic microspheres | Leiden University Medical Center The Netherlands | 2018 - (recruiting)     | NCT03437382                   |               |
| HEPAR Primary: Holmium-166-radioembolization in Hepatocellular Carcinoma Patients | device       | hepatocellular carcinoma           | SIRT Holmium-166 PLLA microspheres | Erasmus Medical Center Rotterdam, University Medical Center Utrecht The Netherlands | 2017 - (recruiting)     | NCT03379844                   |               |
| Feasibility of Holmium-166 Micro Brachytherapy in Head and Neck Tumors | device       | head-and-neck neoplasms            | SIRT Holmium-166 PLLA microspheres | University Medical Center Utrecht The Netherlands             | 2016-2018 (terminated, slow accrual) | NCT02975739                   |               |
| Holmium-166-radioembolization in NET After Lutetium-177-dotatate; an Efficacy Study | device       | neuroendocrine tumours in the liver | SIRT Holmium-166 PLLA microspheres | University Medical Center Utrecht, The Netherlands             | 2016 - (recruiting)     | NCT02067988                   | (Braat et al. 2018b; van Nierop et al. 2018) |
| Surefire Infusion System vs. Standard Microcatheter Use During Holmium-166 Radioembolization | device       | colorectal metastases in the liver | SIRT Holmium-166-PLLA microspheres | University Medical Center Utrecht The Netherlands             | 2016 - (recruiting)     | NCT02208804                   | (van Nierop et al. 2018; van den Hoven et al. 2016) |
| Radioactive Holmium Microspheres for the Treatment of Unresectable Liver Metastases | device       | liver neoplasms                    | SIRT Holmium-166-PLLA microspheres | University Medical Center Utrecht The Netherlands             | 2012-2015 (completed)   | NCT01612325                   | (Prince et al. 2018; Braat et al. 2018a; Prince et al. 2015; van Nierop et al. 2018) |
| Radioactive Holmium Microspheres for the Treatment of Liver Metastases    | device       | liver metastases                   | SIRT Holmium-166-PLLA microspheres | University Medical Center Utrecht, The Netherlands             | 2009–2012 (completed)   | NCT01031784                   | (Smits et al. 2012; van de Maat et al. 2013; Smits et al. 2013; Smits et al. 2010; Prince et al. 2014; Elschot et al. 2014; Braat et al. 2018a; van Nierop et al. 2018) |
| Radiation Therapy Using Holmium                                         | drug         | multiple myeloma                   | melphalan +                         | Fred Hutchinson Cancer                                         | 2004–2010               | NCT00004158                   |               |
| Study title                                                                 | Device/drug                                                                 | Tumour type                                      | Compound                        | Sponsor                                      | Time path   | ClinicalTrials.gov Identifier | Reference(s) |
|-----------------------------------------------------------------------------|------------------------------------------------------------------------------|--------------------------------------------------|----------------------------------|----------------------------------------------|-------------|-------------------------------|---------------|
| Ho 166 DOTMP Plus Melphalan and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma | and plasma cell neoplasm                                                    | Holmium-166- DOTMP                               | Research Center Seattle, Washington, United States | (completed)                     |             |                               |               |
| Melphalan With or Without Holmium Ho 166 DOTMP Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma | drug                                                                         | multiple myeloma and plasma cell neoplasm        | melphalan + Holmium-166- DOTMP  | Fred Hutchinson Cancer Research Center Seattle, Washington, United States | 2004–2010    | NCT00008229                   |               |
| Study Comparing STR (Skeletal Targeted Radiotherapy) Plus Melphalan to Melphalan Alone, With Stem Cell Transplant in Multiple Myeloma | drug                                                                         | multiple myeloma                                 | Holmium-166- DOTMP               | Poniard Pharmaceuticals                    | 2004–2009    | NCT00083564                   | Giralt et al. 2003; Breitz et al. 2003b |
| Holmium Ho 166 DOTMP Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Ewing’s Sarcoma or Rhabdomyosarcoma That Has Spread to the Bone | drug                                                                         | metastatic cancer, sarcoma                        | Holmium-166- DOTMP               | Fred Hutchinson Cancer Research Center Seattle, Washington, United States | 2008–2011    | NCT00006234                   |               |
| Chemotherapy, Holmium Ho 166 DOTMP, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma | drug                                                                         | multiple myeloma and plasma cell neoplasm        | Holmium-166- DOTMP               | Poniard Pharmaceuticals                    | 2003–2009    | NCT00045136                   |               |
| A Trial of Skeletal Targeted Radiotherapy Using Holmium-166-DOTMP in Patients With Multiple Myeloma | drug                                                                         | multiple myeloma                                 | Holmium-166-DOTMP                | Poniard Pharmaceuticals                    | 2002–2009    | NCT00039754                   |               |
Ceramic materials

Another type of intratumoural treatment is brachytherapy (Fig. 3), in which radioactive ceramic materials are implanted in the tumour. These devices can form a variety of shapes and sizes and have been widely used because they can deliver a high local dose to the tumour while the surrounding tissue is spared, and they have shown to be biocompatible and biodegradable (Roberto et al. 2003; Campos et al. 2008). They are usually synthesized by the sol-gel technique which is a chemical method using temperatures below those used in traditional methods to process glass and ceramics (Hench and West 1990). This technique involves the homogenization of several components, pouring into moulds and then following a specific procedure of gelation, aging, drying and heat treatment (Hench and West 1990). The preparation of seeds (Diniz et al. 2017; Valente et al. 2011; Nogueira and Campos 2011; Nogueira and de Campos 2012; Nogueira and Campos 2016) and membranes (Nogueira and de Campos 2012) composed of $^{165}$Ho have been reported in the literature. Seeds usually have dimensions ranging from 0.3 to 0.8 mm in diameter and 1.5 to 1.8 mm in length and a density of 2 to 3.7 g/cm$^3$ (Valente et al. 2011; Nogueira and Campos 2011). Holmium concentrations of 20 wt% (Valente et al. 2011) up to 30 wt% (Nogueira and Campos 2016) are achieved in these materials and it has been shown that the radionuclides are homogeneously distributed in the seeds matrix (Nogueira and Campos 2011). Neutron activation is performed on the final material and, although different elements in the matrix can be neutron activated, it has been shown that the radionuclide impurities are negligible due to low neutron cross-section of the materials used in their fabrication (Nogueira and Campos 2011). Insertion of other elements in the holmium-based ceramic materials such as barium (Nogueira and de Campos 2012) and zirconium (Nogueira and Campos 2016) to improve the radiological contrast allowing visualization of the seeds using conventional X-rays and mammography has also been investigated.

$^{166}$Ho–labelled ceramic seeds have been studied in brain tissue in an animal study and also in a simulation study in human breast tissue (Diniz et al. 2017; de Campos et al. 2016). The advantages of the $^{166}$Ho-labelled seeds are the high dose rate and not having to remove the seeds after the treatment. Diniz et al. investigated the safety of degradable seeds in rat brains, using non-neutron activated seeds. The results showed no neurological or brain architectural changes, indicating a safe procedure (Diniz et al. 2017). In a study on brachytherapy in breast cancer by de Campos et al. a computational simulation was performed to provide a dosimetric analysis of temporary $^{192}$Ir-labelled seeds compared to permanent $^{166}$Ho-labelled seeds. It was shown that the spatial dose distribution of $^{166}$Ho was confined to the implanted volume, whereas this is not the case for brachytherapy using iridium-192, which is frequently used (de Campos et al. 2016). Monte Carlo simulations (Hosseini et al. 2013) and MIRD methodology (Valente and Campos 2010) have been used to determine the range and total absorbed dose of $^{166}$Ho-labelled ceramic seeds. The results were compared with seeds containing $^{32}$P, $^{90}$Y (Hosseini et al. 2013) or samarium-132 ($^{132}$Sm). The radial dose values of the $^{166}$Ho-labelled seeds were concluded to be higher than other seeds at distances smaller than 5 mm (Hosseini et al. 2013; Valente and Campos 2010).
Microspheres

$^{166}$Ho-labelled microspheres ($^{166}$Ho-MS) have been developed for SIRT (also called radioembolization) (see paragraph on Selective internal radiation therapy) (Nijsen et al. 1999; Nijsen et al. 2004; Nijsen et al. 2001), but may potentially be used in microbrachytherapy (Bakker et al. 2017) for treatment of liver tumours (Bult et al. 2013a), kidney tumours (Bult et al. 2012) and head-and-neck tumours (van Nimwegen et al. 2018; Bakker et al. 2018). Moreover, this intratumoural approach can be used also for other tumour types such as pancreas tumours and even lung tumours. The intratumoural potential of $^{166}$Ho-MS has been investigated in both veterinary and human patients (Bakker et al. 2018; Bult et al. 2013a; van Nimwegen et al. 2018; Bult et al. 2013b; Van de Bovenkamp et al. 2009). Currently, two types of $^{166}$Ho-MS for intratumoural application, i.e., $^{166}$Ho-labelled acetylacetonate microspheres ($^{166}$Ho-AcAc-MS) and $^{166}$Ho-labelled poly(L-lactic acid) microspheres ($^{166}$Ho-PLLA-MS) were tested in animals. The $^{166}$Ho-AcAc-MS are prepared by a conventional oil in water (o/w) emulsification and solvent evaporation method by dissolving $^{165}$Ho-labelled AcAc crystals in chloroform and adding this organic solution to an aqueous phase containing an emulsifier. The emulsion formed is stirred until complete evaporation of the chloroform. The method enables preparation of microspheres with different sizes by varying for instance the stirring speed (Bult et al. 2012; Bult et al. 2009). The $^{166}$Ho-PLLA-MS are prepared using a similar method with the exception that the polymer (PLLA) is added to the organic solution before emulsification (Nijsen et al. 1999). After preparation, both microspheres have to be neutron activated to obtain radioactive $^{166}$Ho-AcAc-MS and $^{166}$Ho-PLLA-MS which can later be used for intratumoural treatments. In 2013, the first two papers on $^{166}$Ho-AcAc-MS in microbrachytherapy were published by Bult et al. (Bult et al. 2013a; Bult et al. 2013b). In the first study, the feasibility of applying $^{166}$Ho-AcAc-MS as an intratumoural treatment for renal tumours was demonstrated (Bult et al. 2013b). In the second study three domestic cats with spontaneous liver cancer were treated by administration of $^{166}$Ho-AcAc-MS via ultrasound guided percutaneous injections. In all cats the treatment was well tolerated and life was extended with good quality of life (Bult et al. 2013a). Van Nimwegen et al. treated 13 cats with inoperable squamous cell carcinoma by intratumoural injection of $^{166}$Ho-PLLA-MS. A response rate of 55% was observed with minimal side effects (van Nimwegen et al. 2018). Bakker et al. used $^{166}$Ho-PLLA-MS as a palliative treatment for patients with recurrent head-and-neck squamous cell carcinoma. Due to technical difficulties, a low patient dose and non-homogeneous distribution was observed which is probably the reason that a relatively low therapeutic efficacy was seen, however in none of the cases adverse effects were observed (Bakker et al. 2018).

Holmium solutions

The possibility of using dissolved $^{166}$Ho has also been studied. Suzuki et al. injected dissolved $^{166}$Ho salts into the liver of a male rat, resulting in a high uptake in blood and other tissue, however there was no retention of $^{166}$Ho at the injection site (Suzuki et al. 1998). In a mouse model of melanoma, free $^{166}$Ho was injected into the tumours with one single injection. The injection fluid was not always uniformly distributed throughout the tumours causing tumour regrowth. It
was suggested that free $^{166}$Ho may be used for solid and firm tumours, although hypervascularized tumours may not retain the soluble form (Lee et al. 2002). Tumour growth was increasingly impaired when intratumoural injection of free $^{166}$Ho was combined with the injection of dendritic cells 1 week after $^{166}$Ho injection, compared to $^{166}$Ho injection alone. Nineteen days after $^{166}$Ho injection, the average tumour size in the $^{166}$Ho injection alone group was 1658 mm$^2$, against 444 mm$^2$ in the $^{166}$Ho and dendritic cell group (Lee et al. 2006).

**Intravenous applications**

**Antibodies and peptides**

Targeted therapy with radionuclides is an upcoming form of cancer treatment, in which radioisotopes are labelled to antibodies or other tumour-seeking peptides (Fig. 3). Different antibodies (Table 1) have been conjugated to $^{166}$Ho. For this, (monoclonal) antibodies (mAbs) are first conjugated to an appropriate chelator such as DO3A-4B4 (Ballard et al. 2011), DOTA, methoxy-DOTA (MeO-DOTA) (Mohsin et al. 2006) or CHX-A$^+$ DTPA (DTPA = diethylenetriaminepentaacetic acid) (Thompson et al. 2014). Radiolabeling with $^{166}$Ho is then performed in an appropriate buffer by mixing the antibody-chelator conjugate with the radioactive $^{166}$Ho dissolved in hydrochloric acid. The complex is then purified typically by size exclusion chromatography (Mohsin et al. 2006).

Melanoma is an example of a disease in which labelled antibodies or peptides with $^{166}$Ho have been used as a treatment. Ballard et al. labelled a 4B4 peptide with three types of isotopes, i.e. $^{166}$Ho, $^{177}$Lu and samarium-153 ($^{153}$Sm), as a potential therapy for melanoma. In vitro binding assays demonstrated a lower binding efficiency and specific activity of $^{166}$Ho and $^{153}$Sm compared to $^{177}$Lu, as a result $^{166}$Ho and $^{153}$Sm have not been included in further in vivo experiments (Ballard et al. 2011). In a study by Thompson et al., a comparison was made between $^{166}$Ho-, $^{90}$Y-, and $^{188}$Re-labelled 6D2 mAbs as a potential treatment for melanoma. The results showed a comparable therapeutic effect between $^{166}$Ho- and $^{188}$Re-labelled 6D2 mAbs after injection of an activity of 37 MBq. Additionally, no toxic effect was observed as a result of injection of $^{166}$Ho or $^{188}$Re complex, whereas the $^{90}$Y complex was toxic to mice and did not produce an antitumour effect (Thompson et al. 2014).

Over the years, a strong interest in targeted therapies for colorectal cancer has been developed. In a preclinical study, mice were intravenously injected with $^{166}$Ho-, promethium-149 ($^{149}$Pm)- or $^{177}$Lu-labelled CC49 mAbs 14 days after implantation of human colon tumours. Biodistribution results showed a maximum tumour uptake of $^{166}$Ho at 96 h post injection (Mohsin et al. 2006), which is rather late. Since the half-life of $^{166}$Ho is only 26.8 h, the therapeutic effect may then be limited. In another study the same mAbs and radionuclides were compared and the $^{166}$Ho-labelled mAbs yielded the least favourable results in terms of tumour doubling time and survival (Mohsin et al. 2011). These unfavourable results may also be the result of the combination of short half-life (26.8 h) and late (96 h) maximum tumour uptake, as the $^{166}$Ho may already be decayed when arriving to the tumour. Khorami-Moghada et al. provided a study on a colon cancer model in mice, labelling $^{166}$Ho to the VEGF-A antibody bevacizumab. The biodistribution results show high uptake in the liver, blood, kidneys and in the tumours (Khorami-
Unfortunately, the article is not very clear in its material and methods and therefore it is difficult to estimate the real value.

**Bone-seeking agents**

Bone marrow transplantation poses a potentially curative treatment to various hematologic malignancies. Prior to the autologous or allogeneic transplantation high local radiation doses are needed to destroy the old bone marrow. High doses generated by external radiation may cause damage to other organs, which is unfavourable. Therefore, bone seeking radiopharmaceuticals have been developed to generate a high local dose and limiting dose to other tissues.

An efficient and safe radiopharmaceutical for bone marrow ablation requires the formation of a stable complex between the bone-seeking agent and the radionuclide. Phosphonate chelates are commonly used for this purpose due to their excellent specificity for bone localization. When combined with radioactive isotopes, the complexes can deliver high levels of radiation to bone and bone marrow, leaving normal tissues unaffected. The isotope $^{166}\text{Ho}$ has been conjugated to several bone-seeking agents for bone marrow ablation such as EDTMP (ethylene-diamine-tetramethylene phosphonic acid) (Sohaib et al. 2011; Bahrami-Samani et al. 2010; Appelbaum et al. 1992; Louw et al. 1996), DOTMP (Bayouth et al. 1995a; Bayouth et al. 1995b; Parks et al. 1993; Giralt et al. 2003; Breitz et al. 2006; Rajendran et al. 2002; Ueno et al. 2009; Breitz et al. 2003a), TTHMP (triethylene tetramine hexa (methylene phosphonic acid)) (Yousefnia et al. 2014), PAM (pamidronate) (Vaez-Tehrani et al. 2016), APDDMP (N,N-dimethylene-nephosphonate-1-hydroxy-4-aminopropylidene-diphosphonate) (Marques et al. 2006; Zeevaart et al. 2001), among others. The preparation of the $^{166}\text{Ho}$-radiolabelled complexes is performed very similarly with the different bone-seeking agents. In general, a target of holmium oxide is neutron activated which is afterwards dissolved in hydrochloric acid to form $^{166}\text{HoCl}_3$. Then, a solution containing the dissolved chelator complex (e.g. DOTMP) is added and the pH is adjusted to 7–8. Complexation occurs within typically 1 h at room temperature with high radiochemical purity (more than 99%) (Sohaib et al. 2011; Bahrami-Samani et al. 2010; Bayouth et al. 1995a; Yousefnia et al. 2014).

Appelbaum et al. showed that after 24 h post injection of the bone seeking phosphonate EDTMP labelled with $^{166}\text{Ho}$, the $^{166}\text{Ho}$EDTMP concentration was 200-fold higher in bone than in other organs (Appelbaum et al. 1992). The results of a study performed by Bahrami-Samani et al. in wild-type rats demonstrated significant bone accumulation (> 70%) of $^{166}\text{Ho}$EDTMP after 48 h (Bahrami-Samani et al. 2010). However, in a study by Louw et al., $^{166}\text{Ho}$EDTMP turned out to be significantly inferior to $^{153}\text{Sm}$EDTMP in terms of pharmacokinetics, biodistribution and skeletal localization (Louw et al. 1996). These results differ considerably from the results found by Appelbaum et al. (Appelbaum et al. 1992). The discrepancy might, among others, be due to the use of S-values for human children by Appelbaum et al., whereas adult human S-values were used by Louw et al. (Louw et al. 1996). Sohaib et al. also demonstrated inferiority of $^{166}\text{Ho}$EDTMP compared to $^{90}\text{Y}$EDTMP, with a
skeletal accumulation of only approximately 27% (46% in $^{90}$Y EDTMP) (Sohaib et al. 2011).

Pedraza-Lopez et al. have labelled $^{166}$Dy/$^{166}$Ho with the bone seeker EDTMP to treat haematological malignancies. $^{166}$Dy$_2$O$_3$ was neutron activated and converted to $^{166}$DyCl$_3$ which was then added to a solution containing EDTMP in phosphate buffer (pH 8.0). A radiochemical purity of 99.3 ± 0.6% was achieved. Animal studies showed a fast blood clearance of $[^{166}\text{Dy}]^{166}\text{Dy}/[^{166}\text{Ho}]^{166}\text{Ho}$ EDTMP and a skeletal uptake of 22.32 ± 1.86% ID/g at 2 h and 20.12 ± 1.94% ID/g after 10 days. Theoretical bone marrow absorbed dose calculations indicate that the $[^{166}\text{Dy}]^{166}\text{Dy}/[^{166}\text{Ho}]^{166}\text{Ho}$ EDTMP in vivo generator system produced 3.47 times more dose than $[^{166}\text{Ho}]^{166}\text{Ho}$ DOTMP per unit of initial activity in the skeleton (Pedraza-Lopez et al. 2004a). The same group also demonstrated that the $[^{166}\text{Dy}]^{166}\text{Dy}/[^{166}\text{Ho}]^{166}\text{Ho}$ EDTMP system induced considerable cytotoxicity, genotoxicity and severe myelosuppression in mice at bone marrow absorbed doses of 18–23 Gy, suggesting that this system could potentially be a good agent for use in humans (Pedraza-Lopez et al. 2004b).

In an animal study on splenectomized young adult beagle dogs, a complete ablation of hematopoietic marrow was seen within 7 days after receiving a radiopharmaceutical dosage of 370 MBq/kg body weight of $[^{166}\text{Ho}]^{166}\text{Ho}$ DOTMP (Parks et al. 1993). The pharmacokinetics, biodistribution and absorbed dose estimation of the $[^{166}\text{Ho}]^{166}\text{Ho}$ DOTMP complex has also been studied in six patients suffering from multiple myeloma. A high uptake in the skeleton and rapid clearance from the blood was observed (Bayouth et al. 1995a). Two larger phase I/II dose escalation studies in human patients showed a fast bone uptake, rapid clearance from the blood, no retention in soft tissue and minimal systemic toxicity (Giralt et al. 2003; Rajendran et al. 2002). A therapeutic dose of $[^{166}\text{Ho}]^{166}\text{Ho}$ DOTMP was given to 83 patients with multiple myeloma. In 35% of the patients complete remission was achieved and no acute toxicity issues were seen (Giralt et al. 2003). In this cohort study, dosimetry and toxicity were also assessed. Doses in the marrow, bladder and kidney range from 13 to 59 Gy, 4.7 to 157 Gy, and 0.5 to 7.9 Gy, respectively. Hemorrhagic cystitis was observed in a number of patients who received a dose of more than 40 Gy to the bladder wall. Renal toxicity related to $[^{166}\text{Ho}]^{166}\text{Ho}$ DOTMP was observed in 7 patients (12%) (Breitz et al. 2003a). Ueno et al. treated 6 women with bone-only metastasized breast cancer with $[^{166}\text{Ho}]^{166}\text{Ho}$ DOTMP. After a follow-up time of 6 years, 2 of the 6 patients sustained complete response. An acceptable toxicity profile was also described in this paper (Ueno et al. 2009). Since the results are very promising, five clinical trials have been performed on $[^{166}\text{Ho}]^{166}\text{Ho}$ DOTMP, of which no papers have been published yet, with the following clinicaltrials.gov identifier numbers: NCT00045136, NCT00004158, NCT00008229, NCT00039754, NCT0006234 (Table 2).

Vosoghi et al. developed a highly-stable metallic organic framework (MOF) as a bone seeking agent composed of DOTMP, $^{166}$Dy/$^{166}$Ho generator and CuCl$_2$. The MOF was formed by stirring neutron activated $[^{166}\text{Dy}]^{166}\text{Dy}/[^{166}\text{Ho}]^{166}\text{Ho}$ nitrate, CuCl$_2$ and DOTMP at room temperature. Purification of the $^{166}$Dy from the $^{166}$Ho and other isotopes was achieved by chromatography before preparation of the MOF. The particles obtained had a size ranging from 60 to 100 nm. The product has shown to have high affinity for simulated bone matrix and comparable to that of the FDA-approved radiopharmaceutical Quadramet ($[^{153}\text{Sm}]^{153}\text{Sm}$ EDTMP) (Vosoghi et al. 2016).
Two other bone-seeking agents are nano-hydroxyapatite dopped with $^{166}$Ho (da Silva et al. 2017) and $^{[166]}$Ho PDTMP (Zolghadri et al. 2013). In both studies, a significant bone uptake was demonstrated, but no further research has been done.

**Nanoparticles**

Nanoparticles containing holmium have been used for different applications with different compositions (Table 1). Munaweera et al. developed magnetic nanoparticles containing both $^{166}$Ho and a platinum-based chemotherapeutic to treat lung cancer. This study demonstrated that the nanoparticles are toxic to the tumour cells and that tumour to liver ratios increases when an external magnetic field was applied (Munaweera et al. 2015). Zielhuis et al. prepared nanosized liposomes (~120 nm) using a conventional thin-film hydration technique and loaded the liposomes with the radioactive $^{[166]}$Ho DTPA-lipid complex which was incorporated in the liposomal bilayer. The high stability and paramagnetic properties make them suitable for treatment and multimodal imaging with SPECT and MRI (Zielhuis et al. 2006).

**Selective internal radiation therapy**

Selective internal radiation therapy (SIRT, also called radioembolization) is a form of internal radiation therapy, during which millions of microspheres are administered into an artery, close to a target lesion. These microspheres of around 30 μm in diameter are administered through a catheter and carried by the blood flow until they lodge at the arteriolar level. Clinically, SIRT is applied as novel treatment for liver malignancies. The rationale is that liver tumours mainly depend on the hepatic artery for their blood supply, whereas the healthy liver tissue is mainly supplied by the portal vein. Therefore, microspheres in the hepatic artery will especially target liver tumours. This will result in a higher radiation dose to the liver tumours, whilst sparing the healthy liver tissue (Nijsen et al. 2002a).

Currently, the only commercially available and clinically used microspheres for SIRT based on the isotope $^{166}$Ho are $^{166}$Ho-PLLA-MS (QuiremSpheres, Quirem Medical, the Netherlands). Other microspheres with $^{166}$Ho that were investigated for application within SIRT procedures are MS-PDLLA-HoAcAc (Nayak and Lahiri 1999) and resin-based microspheres from Turner et al. (Turner et al. 1994; Zielhuis et al. 2007; Mumper and Jay 1992). The polymer-based microspheres used for SIRT are typically prepared by the emulsification and solvent evaporation method (see section 3.3) and have the advantage of near blood plasma density and biocompatibility (Nijsen et al. 2002a; Mumper et al. 1992). However, polymers are usually sensitive to neutron irradiation which can lead to damage of the microspheres after long neutron activation (Nijsen et al. 1999; Nijsen et al. 2002b). Nevertheless, the $^{166}$Ho-PLLA-MS microspheres can be neutron activated till high amounts of activity, sufficient for transportation to the hospital and clinical application (Vente et al. 2009). Resin-based microspheres present the advantage of easier preparation performed through the incubation of the radioactive $^{166}$Ho with commercially available resins. Bio-Rex resins which are made of an acrylic polymer with carboxylic groups were used to bind $^{166}$Ho with high-yield (94.53% at pH 8.5) by Subramanian et al. (Subramanian et al. 2018). Aminex A-5 resin, based on styrene divinylbenzene copolymer with sulphonic acid, has also...
been conjugated to $^{166}$Ho by Turner et al. (Turner et al. 1994). Alginate microspheres can also be loaded with $^{166}$Ho after neutron activation (Das et al. 2009a). Last, chitosan microspheres containing the $^{166}$Dy/$^{166}$Ho in vivo generator have also been prepared. Stability studies showed that 5–10% of the radioactivity was released in human serum (Cho and Choi 2018).

**Imaging (SPECT, MRI and CT)**

Smits et al. described that the activity for using holmium microspheres in SIRT can be calculated with the following formula: $A_{Ho166}$ (MBq) = Liver dose × 63 (MBq/l) × LW (kg) where $A_{Ho166}$ is the administered activity, LW is the tissue weight, and dose is the intended absorbed radiation dose in Gy (Smits et al. 2012; van de Maat et al. 2013).

When imaging the $^{166}$Ho distribution with SPECT, medium-energy collimators are often used with energy windows of 80.6 keV (15% window width) for the $^{166}$Ho photo-peak and 118 keV (12%) for correction for down-scattered high-energy photons. A typical protocol will be 120 projections of 30 s orbits around the liver. Data for the distribution of $^{166}$Ho-PLLA-MS deposition in liver SIRT treatments have been reconstructed to a 128 · 128 · 128 matrix with an isotropic voxel size of 4.7 mm or 4.8 mm using an ordered-subsets expectation maximization algorithm including resolution recovery and a hybrid method for scatter and attenuation correction (Elschot et al. 2011; Smits et al. 2013).

The holmium in the microspheres can be used for quantitative MR imaging, since it is a highly paramagnetic metal. The imaging is usually performed on clinical whole-body MR systems of 1.5 or 3 T (Smits et al. 2013). For quantitative measurements of the $^{166}$Ho-microsphere biodistribution, a multi-slice multi-gradient echo sequence is used, sampling the MR imaging signal of the free induction decay. The holmium quantification is performed though T2*-weighted turbo spin echo imaging (Seevinck et al. 2007; van de Maat et al. 2013; Smits et al. 2013; Seevinck et al. 2012).

Agglomerations of holmium microspheres can be visualized through CT imaging, in practice especially holmium microspheres that contain relatively high amounts of holmium. If these microspheres are concentrated, which is the case in intratumoural injections, CT can be used for quantitative detection (Seevinck et al. 2007; Bakker et al. 2018). Moreover, novel microspheres with a much higher holmium content are currently developed (Bult et al. 2009; Arranja et al. 2018). These microspheres are expected to be visible on CT in even lower concentrations.

**Head-and-neck tumours**

Van Es et al. performed two animal studies in which Vx2 cells were subcutaneously injected into the auricles of rabbits. After reaching a tumour size of 4 cm$^2$, $^{165/166}$Ho-PLLA-MS (van Es et al. 2001; Van Es et al. 2001) or $^{99m}$Tc-labelled Dextran hydrogel (Dex) MS (van Es et al. 2001) were injected into the caudal auricular artery. In the first study a comparison was made between injecting $^{165}$Ho-PLLA-MS and $^{166}$Ho-PLLA-MS. Complete remission of 79% and 86% was obtained by injecting $^{165}$Ho-PLLA-MS and $^{166}$Ho-PLLA-MS, respectively. Although there was a high remission rate, the limited additional effect of irradiation might be explained...
by the high sensitivity of the Vx2 tumour model to vascular occlusion. In addition, retention of approximately 40% of the MS into the infusion system may have led to an ineffective dosage (Van Es et al. 2001). In the second study, injection of $^{166}$Ho-PLLA-MS was compared to Dex MS. 51% of the $^{166}$Ho-PLLA-MS, with a diameter of 19 μm, shunted to the lungs, whereas 95% of the Dex MS were retained in the tumour (van Es et al. 2001).

Liver tumours

In a biodistribution study in which SIRT was performed with $^{166}$Ho-PLLA-MS on rats with implanted liver tumours, the radioactivity in the tumours was six time higher than in the non-targeted liver tissue, indicating the $^{166}$Ho-PLLA-MS deposition was confined to the liver (Nijsen et al. 2001). In order to assess the clinical effects of the microspheres, healthy pigs received an activity up to 6.5 GBq through the liver artery, which corresponds with an estimated absorbed liver dose of 120 Gy. After 2 months of follow-up, it was concluded that the toxicity profile of holmium microspheres is low and that administration of doses up to 100 Gy is not associated with clinically relevant side effects (Vente et al. 2008).

Seppenwoolde and his colleagues demonstrated the feasibility of fully MR-guided SIRT with holmium microspheres in pigs. Whereas the positioning of the catheter normally takes place under X-ray guidance, in this study a passive tracking sequence was used to visualize paramagnetic markers on the catheter. Although some drawbacks are described (such as difficulty in visualization of the catheter due to respiratory motion artefacts) this article is the first to report on real-time imaging of holmium microspheres in an anthropomorphomorphic in vivo model as a proof of principle that real-time image guided treatment is possible under MRI (Seppenwoolde et al. 2005).

The first clinical trial in which $^{166}$Ho-PLLA-MS were administered to patients was the phase 1 HEPAR 1 trial (2009–2011) (Smits et al. 2012; Smits et al. 2010) (Table 2). In this study, 15 patients with liver metastases of any origin were treated by SIRT at different whole-liver absorbed dose levels ranging from 20 to 80 Gy (Fig. 4). In the 80 Gy cohort, dose-limiting toxicity occurred in two out of three patients. Therefore, the maximum tolerated radiation dose was identified as

![Fig. 4](image-url)
60 Gy. Exposure rates (μSv/h) from patients were measured at 1.0 m distance from a lateral and frontal position at 0, 3, 6, 24, and 48 h after infusion. The total effective dose equivalent to a contact of patients treated with $^{166}$Ho-labelled MS did not exceed the NRC limit of 5 mSv. Contact restrictions 6 h after treatment are unnecessary for infused activities < 7 GBq (Prince et al. 2014).

After SIRT of liver metastases with $^{166}$Ho-PLLA-MS was deemed safe in the HEPAR 1 trial, the HEPAR 2 trial was performed to investigate the efficacy of the $^{166}$Ho SIRT (Prince et al. 2018) (Table 2). In this trial, 38 patients with liver metastases refractory to systemic therapy and ineligible for surgical resection were treated with $^{166}$Ho-PLLA-MS. In 73% of the patients, the target lesions showed complete response, partial response, or stable disease (disease control) at 3 months. There was an acceptable toxicity profile. The most common adverse events during follow-up were gastrointestinal complaints, i.e. nausea, abdominal pain and fatigue. In a subgroup analysis on the patients with liver-dominant colorectal cancer metastases, a median survival of 13.4 months (95% CI, 8.2–15.7 mo) was seen, which is comparable to the reported range of 8.3–15.2 mo after $^{90}$Y SIRT (Prince et al. 2018).

In order to prevent any unintentional deposition of the microspheres in tissue other than the liver, a safety procedure is typically performed before the actual treatment. During this procedure, relevant extrahepatic arteries are coiled and a scout dose of technetium-99 m-labelled macro-aggregated albumin ($^{99m}$Tc-MAA) is administered. SPECT-imaging is then performed in order to estimate the extrahepatic shunting of activity. In literature, it has been argued multiple times that this $^{99m}$Tc-MAA scout dose is not an accurate estimation of the actual microsphere distribution, due to morphological (different non-spherical shapes, large size distribution) and biochemical differences between $^{99m}$Tc-MAA and microspheres such as $^{166}$Ho-labelled MS and $^{90}$Y-labelled MS (Wondergem et al. 2013; Elschot et al. 2014).

For this matter, studies have been performed to investigate the possibility of using a scout dose of $^{166}$Ho-labelled MS ($^{166}$Ho-SD) before treatment. Braat et al. (Braat et al. 2018a) used a scout dose (250 MBq) in 82 patients. In 6 patients there were extrahepatic depositions, however, no adverse events related to this were observed during a median follow-up of 4 months (range 1–12 months). In another study, the extrahepatic depositions of $^{99m}$Tc-MAA were objectified in 166 patients, and then the absorbed dose was calculated as if these patients had received a $^{166}$Ho-SD. Only in 2 cases the theoretical dose exceeded 50 Gy (Prince et al. 2015). These results support the safety of a 250 MBq $^{166}$Ho-SD in a clinical setting.

Radosa et al. investigated the clinical feasibility, technical success and toxicity of SIRT with $^{166}$Ho-labelled MS in 9 patients with HCC (Radosa et al. 2019). The median administered activity was 3.7 GBq. The treatment was found to be feasible and safe, with no significant hepatotoxicity, as 4 patients suffered from mild and transient post radioembolization syndrome and no indicators of SIRT induced liver disease (REILD) were observed. Eight patients showed a good response and only one patient had a progressive disease at 6 months follow-up. All in all, the results with holmium microspheres were deemed at least comparable to yttrium microspheres in terms of safety.
Radiosynoviorthesis

**Ferric hydroxide macroaggregates**

Besides cancer treatment, $^{166}$Ho may also be used as a radionuclide in a technique called radiosynoviorthesis to treat chronic synovitis or recurrent hemorrhrosis in coagulation disorders. In this treatment, a $^{166}$Ho-labelled ferric hydroxide macroaggregates (FHMA) complex is injected into the affected joints (Fig. 3) to generate local irradiation. Various studies have been performed on this type of treatment. In a Monte Carlo simulation study by Ferro-Flores et al. it was shown that $^{166}$Ho generates a favourable radiation dose to the articular cartilage and bone surface (Ferro-Flores et al. 2004). In an animal study, 30 rabbits received intra-articular injections with $^{166}$Ho-labelled FHMA, resulting in acute focal radiation necrosis without hyperplasia of synoviocytes. Autoradiography showed an uneven distribution of the radiotherapeutical along the synovial lining. After 3 days, the majority of the $^{166}$Ho-labelled FHMA complex had leaked out of the joint or was phagocytized by the synoviocytes (Makela et al. 2002). In a study by Makela et al., six horses were treated with $^{166}$Ho-labelled FHMA, with a mean activity of 1000 MBq/joint. $^{165}$Ho-labelled FHMA was used as a control. In this study, acute focal radiation necrosis (of the synovium) was observed as well, but in contrast to the study on rabbits, no radiopharmaceutical leakage was found (Makela et al. 2003a). The articular cartilage of the horses showed only mild signs of degeneration as a result of this therapy (Makela et al. 2004). In another study, the short and long-term effects of radiosynoviorthesis with $^{166}$Ho-labelled FHMA were observed in mature and growing rabbits. The radiation effects in the growing rabbits included mild cartilage fibrillation and downregulation of cartilage-specific genes (Makela et al. 2003b). In a study by Vuorela et al., SPECT and MRI images of human patients treated with $^{166}$Ho-labelled FHMA were fused. SPECT images were used to localize the $^{166}$Ho, whereas the T1-weighted Gd-DTPA MR images were used to visualize the inflamed synovium. A higher uptake of $^{166}$Ho in regions associated with a higher level of synovitis was seen (Vuorela et al. 2005). Kraft et al. studied the therapeutic effect of $^{166}$Ho-labelled boron macroaggregates. In this study, 17 knees of 15 human patients with chronic synovitis were treated with a mean activity of 972 MBq. Only an insignificant leakage of radiopharmaceuticals was observed. Six months after treatment, 73% of the patients experienced a lower sense of pain. In addition, 2 patients had no knee exudation anymore and a decrease of knee exudation was seen in 4 patients (Kraft et al. 2007).

**Chitosan**

Synovitis can also be treated with intra-articularly injected $^{166}$Ho-labelled chitosan. The preparation of the complex is similar to the one used for intratumoural application (section 3.1). In a study on human patients with rheumatoid arthritis, most of the injected radioactivity was localized within the injected cavity and limited radioactive excretion and negligible extra-articular leakage were observed (Cho et al. 2010; Song et al. 2001). Cho et al. stated that $^{166}$Ho-labelled chitosan is a favourable agent compared to the conventional treatment of synovitis using other radioisotopes, based on a higher permeability to soft tissue, smaller extra-articular leakage and higher amount of induced synovial necrosis (Cho et al. 2010). Lee et al. evaluated the response using MR
imaging and found decreased joint effusion at 4 months after the treatment with $^{166}$Ho-labelled chitosan (Lee et al. 2003).

**Microspheres**

Next to SIRT, $^{166}$Ho-PLLA-MS have also been studied as an agent for radionuclide synovectomy. In a study by Mumper et al., $^{166}$Ho-PLLA-MS were injected in the knee joints of six healthy rabbits. At 120 h post injection, intra-articular $^{166}$Ho retention of approximately 98% was found with no uptake in the lymph nodes (Mumper et al. 1992).

$^{166}$Dy/$^{166}$Ho macroaggregates

Several $^{166}$Dy/$^{166}$Ho-labelled macroaggregates have also been prepared for radiation synovitis (Park et al. 1996; McLaren et al. 1990; Sledge et al. 1977) with promising results in patients (Edmonds et al. 1994). Ferro-Flores et al. also developed $^{166}$Dy/$^{166}$Ho-labelled hydroxide macroaggregates (HM) for radiation synovectomy. For this, $^{164}$Dy$_2$O$_3$ was neutron activated which was then converted into $^{166}$DyCl$_3$ and the $^{166}$Dy isotope purified. The $^{166}$DyCl$_3$ was then incubated with a sodium hydroxide solution in an ultrasonic bath to form $^{166}$Dy/$^{166}$Ho-labelled HM with sizes ranging from 2 to 5 μm and more than 99.5% of radiochemical purity. In vivo studies in rats showed that the $^{166}$Dy/$^{166}$Ho-labelled HM were retained at the administration site even after 7 days (Ferro-Flores et al. 2004).

**Miscellaneous applications**

**Intraluminal irradiation**

Another application of $^{166}$Ho is for intraluminal irradiation, in which typically stenoses or other blood vessel wall abnormalities are treated. Different approaches for intraluminal irradiation have been studied, e.g. $^{166}$Ho-impregnated polyurethane coating on a stent (Won et al. 2002; Won et al. 2005), $^{166}$Ho-coated surface of a dilatation balloon (Kim et al. 2003; Hong et al. 2003) or dilatation balloons filled with $^{166}$Ho conjugated to DTPA (Hong et al. 2004; Park et al. 2007; Park et al. 2003; Kim et al. 2000). Won et al. developed self-expandable stents covered with $^{166}$Ho in a canine model. Both studies demonstrate the formation of fibrosis on the adjacent wall. No serious complications have been reported and it was indicated that this type of stent could be used as an alternative treatment (Won et al. 2002; Won et al. 2005). Hong et al. developed a procedure in which the surface of a dilatation balloon could be coated with $^{166}$Ho. Herein is was stated that coated balloons are more resistant to leaking radioactivity as opposed to liquid $[^{166}$Ho]Ho DTPA filled balloons and a higher dose may be delivered. However, there may be a chance of peeling off of the $^{166}$Ho-coated surface and the activity can be unevenly distributed (Hong et al. 2003). Kim et al. delivered a dose of 20 Gy, using a dilatation balloon with $^{166}$Ho coated on the surface, in a porcine coronary stent restenosis model and the irradiated group demonstrated a significantly decreased stenosis area compared to the control group (Kim et al. 2003). As already mentioned, $^{166}$Ho is also used in combination with DTPA. In a study in rats and rabbits it was shown that after intravenous injection $[^{166}$Ho]Ho DTPA was excreted relatively quickly to the urine bladder. Furthermore, a relatively low absorption in vital organs was seen (Hong et al. 2002). In a phantom study, in which clinically relevant irradiation and duration of exposure were tested, it was shown that $[^{166}$Ho]Ho DTPA is a good source for endovascular irradiation (Joh et al.
This was confirmed in a study in 12 pigs, in which an average dose of 30 Gy was delivered to treat pseudointimal hyperplasia (Park et al. 2007). The feasibility of the treatment to prevent restenosis was also demonstrated by Kim et al. in an animal study on 34 pigs (Kim et al. 2000). Park et al. conducted a study on 56 patients with in-stent restenosis. A balloon filled with liquid $[^{166}\text{Ho}]$Ho DTPA which was a little longer than the stenosed stent was placed inside the lesion. For all patients the treatment was successful, and in 93% of the patients no restenosis occurred within the time of follow-up (approximately 19 months) (Park et al. 2003). Hong et al. tested whether it would be beneficial to combine $[^{166}\text{Ho}]$Ho DTPA with a CT contrast medium. It was demonstrated that a CT contrast medium may have an added value to detect radiation leakage of the balloon on real-time basis (Hong et al. 2004). Majali et al. studied the potential of $[^{166}\text{Ho}]$Ho dimethyl diethylene triamine penta acetic acid (DMDTPA) for intraluminal irradiation in mice. Biodistribution data demonstrated a faster clearance of the complex compared to $[^{166}\text{Ho}]$Ho DTPA, almost no accumulation in bone or any other vital organs was seen (Majali et al. 2002).

**Patches**

Patches for the treatment of skin cancer and Bowen’s disease (a precursor of squamous cell skin cancer) containing $^{166}$Ho have also been fabricated. Lee et al. created patches in which $^{166}$Ho-labelled macroaggregates were attached to an adhesive tape followed by coating with a polyethylene film, where after the patch was neutron-activated. These were then applied to mice with induced skin tumours (Lee et al. 1997). Chung et al. also created a patch to treat skin malignancies by dissolving holmium-nitrate and polyurethane in a solvent mixture of dimethylformamide and tetrahydrofuran and the solution was casted on an aluminium dish until solvent evaporation and consequent formation of a dried film. Particles of 30 to 50 μm were obtained from this cast, neutron activated and afterwards attached to adhesive tape. These patches were applied to patients with Bowen’s disease (Chung et al. 2000). The results of both studies were positive and complete remission was observed. However, they also described several disadvantages, such as the limited penetration depth of the beta radiation, which makes it hard to irradiate bulky tumours. Another disadvantage of patches to which macroaggregates are attached is the chance of isotope...
leakage, which may lead to contamination. Manuweera et al. developed a bandage of nanofibers containing homogeneously incorporated holmium nanoparticles (Munaweera et al. 2014). First, \(^{165}\text{Ho}\)-labelled iron garnet nanoparticles \((^{165}\text{HoIG})\) were prepared by mixing iron nitrate and holmium nitrate with ethylene glycol followed by precipitation of the \(^{165}\text{HoIG}\) nanoparticles with sodium hydroxide. This resulted in nanoparticles with a length of 55 nm and a width of 28 nm. Then, electrospinning of a solution containing polyacrylonitrile (PAN) and the \(^{165}\text{HoIG}\) nanoparticles dispersed in dimethylformamide resulted in a bandage containing nanofibers with the nanoparticles incorporated (Fig. 5). The \(^{165}\text{HoIG}/\text{PAN}\) nanofibers were neutron activated and showed to be stable up to a thermal neutron-flux of approximately \(3.5 \times 10^{12} \text{ neutrons/cm}^2 \text{s}\) for at least 4 h at 100 °C. Stability studies using simulated body fluid revealed no leakage of the nanoparticles from the nanofibers after 8 h incubation (Munaweera et al. 2014).

Radiovertebroplasty

In order to treat bone malignancies a new type of treatment named radiovertebroplasty has been developed. In this therapy, radionuclides are incorporated in bone cement to generate a local high dose. For example, Hirsch et al. developed an acrylic cement of polymethyl methacrylate (PMMA) and uniformly incorporated \(^{166}\text{Ho}\). The authors concluded \(^{166}\text{Ho}\) is a potential radionuclide for radiovertebroplasty based on dosimetry (Hirsch et al. 2008). Donanzam et al. managed to generate stable bioceramics using the sol-gel technique (see section 3.2) in which \(^{166}\text{Ho}\) is incorporated in calcium phosphate. Despite the described potential of the developed biomaterial, clinical trials are necessary to further investigate the bioactivity and efficacy in bone malignancies (Donanzam et al. 2013).

Conclusion

In this review, we have described the broad spectrum of medical applications of \(^{166}\text{Ho}\) as a result of the growing research interest over the years. \(^{166}\text{Ho}\) is among the most promising relatively new therapeutic radioisotopes. Holmium has very interesting physical properties: a high energy beta particle emission for treatment, a low energy gamma photon emission for imaging and a high magnetic susceptibility for MR imaging. Therefore, \(^{166}\text{Ho}\) labelled systems are attractive for radionuclide treatment. Furthermore, because of its natural abundance of 100% and a high cross section of 64 b it can be produced in a straightforward manner, both fast and therefore relatively low-priced. In the radionuclide therapies, it is observed that quantitative analyses and dosimetry are gaining more and more importance to predict treatment efficacy. The value of treatment verification as an integral part of any radiotherapeutic treatment is also underpinned by the Council Directive 2013/59/EURATOM, which came into effect in February 2018, stating: “For all medical exposure of patients for radiotherapeutic purposes, exposures of target volumes shall be individually planned, and their delivery appropriately verified ...”. Imaging and dosimetry can be used for better patient selection and to improve treatment dose calculations. The multimodal imaging medical isotope \(^{166}\text{Ho}\) can be a good response to the increasing demand of more personalized treatments in patients.
Abbreviations

- $^{166}$Ho-SD: A scout dose of $^{166}$Ho-MS
- $^{99m}$Tc-MAA: Technetium-99m-labelled macro-aggregated albumin
- AcAc: Acetylacetonate
- APDDMP: N,N-dimethylenephosphonate-1-hydroxy-4-aminopropylidenediphosphonate
- CT: Computed tomography
- Dex: Dextran hydrogel
- DMDTPA: Di ethylene triamine penta acetic acid
- DMF: Dimethylformamide
- DOTMP: 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylene-phosphonic acid
- DTPA: Diethylenetriaminepentaacetic acid
- EBRT: External beam radiotherapy
- EDTMP: Ethylene-diamine-tetramethylene phosphonic acid
- FHMA: Ferric hydroxide macroaggregates
- HCC: Hepatocellular carcinoma
- HM: Hydroxide macroaggregates
- mAbs: monoclonal antibodies
- MOF: Metallic organic framework
- MRI: Magnetic resonance imaging
- MS: Microspheres
- PAM: Pamidronate
- PAN: Polyacrylonitrile
- PLLA: Poly(L-lactic acid)
- PMMA: Polymethyl methacrylate
- REILD: Radioembolization induced liver disease
- SIRT: Selective internal radiation therapy
- SPECT: Single photon emission computed tomography
- TTHMP: Triethylene tetramine hexa (methylene phosphonic acid)

Acknowledgements

N.a.

Authors’ contributions

NJMK, MJA, AGA and JFWN conceived the general outline of the review. All authors performed the literature search on their topic, reviewed the literature at specific chapters and wrote the manuscript. All authors read and approved of the final manuscript.

Funding

N.a.

Availability of data and materials

N.a.

Ethics approval and consent to participate

N.a.

Consent for publication

N.a.

Competing interests

J.F.W. Nijsen is inventor on the patents related to holmium microspheres which are assigned to University Medical Center Utrecht Holding BV and/or Quirem Medical. He is co-founder and chief scientific officer of Quirem Medical, and has a minority share in the company Quirem Medical. The activities of J.F.W. Nijsen within Quirem Medical are approved and supported by Dirkjan Masman (Director Technology Transfer Office Radboudumc) and Mathias Prokop (Head of Radiology and Nuclear Medicine at Radboudumc).

Author details

1Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Radboud Institute for Health Sciences, Geert Grooteplein Zuid 10, 6525, GA, Nijmegen, The Netherlands. 2Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Science for Life, Faculty of Science, Utrecht University, 3508, TB, Utrecht, The Netherlands. 3Department of Radiation Science and Technology, Delft University of Technology, Mekelweg 15, 2629, JB, Delft, The Netherlands.

Received: 16 April 2019 Accepted: 5 July 2019
Published online: 05 August 2019

References

Appelbaum FR, Brown PA, Sandmaier BM, Storb R, Fisher DR, Shulman HM, Graham TC, Schuening FG, Deeg HJ, Bianco JA, et al. Specific marrow ablation before marrow transplantation using an aminophosphonic acid conjugate $^{166}$Ho-EDTMP. Blood. 1992;80(6):1608–13.

Arranja AG, et al. Radioactive holmium phosphate microspheres for cancer treatment. Int J Pharm. 2018;548(1):73–81.

Bahrami-Samani A, Bagheri R, Jalilian AR, Shirvani-Arani S, Ghannadi-Maragheh M, Shamsaei M. Production, quality control and pharmacokinetic studies of Ho-EDTMP for therapeutic applications. Sci Pharm. 2010;78(3):423–33.

Bakker RC, van Es RJJ, Rosenberg AJWP, van Nimwegen SA, Bastiaannet R, de Jong HWAM, Nijsen JFW, Lam MGEH. Intratumoral injection of radioactive holmium-166 microspheres in recurrent head and neck squamous cell carcinoma: preliminary results of first use. Nucl Med Commun. 2018;39(3):213–21.

Bakker RC, et al. Intratumoral treatment with radioactive beta-emitting microparticles: a systematic review. J Radiat Oncol. 2017;6(4):323–41.

Ballard B, Jiang Z, Soll CE, Revskaya E, Cutler CS, Dadachova E, Francesconi LC. In vitro and in vivo evaluation of melanin-binding decapeptide 4B4 radiolabeled with $^{177}$Lu, $^{166}$Ho, and $^{153}$Sm radiolanthanides for the purpose of targeted radionuclide therapy of melanoma. Cancer Biother Radiopharm. 2011; 26(5):547–56.

Bayouth JE, et al. Pharmacokinetics, dosimetry and toxicity of holmium-166-DOTMP for bone marrow ablation in multiple myeloma. J Nucl Med. 1995a;36(5):730–7.

Bayouth JE, et al. Radiation dose distribution within the bone marrow of patients receiving holmium-166-labeled-phosphonate for marrow ablation. Med Phys. 1995b(22)(6):743–53.

Bernardes EMD. Holmium-166m multi-gamma standard to determine the activity of radionuclides in semiconductor detectors. Int Nucl Inf Syst. 2001;43(50):1–76.
Braat A, et al. Safety analysis ofholmium-166 microsphere scout dose imaging during radioembolisation work-up: a cohort study. Eur Radiol. 2018a;28(1):920–8.

Braat A, et al. Additional hepatic Ho-166-radioembolisation in patients with neuroendocrine tumours treated with Lu-177-DOTATATE: a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial). BMC Gastroenterol. 2018b;18(1).

Breitz H, Wondr R, Stabin M, Bouchet L, Wessels B. Dosimetry of high dose skeletal targeted radiotherapy (STR) with 166Ho-DOTMP. Cancer Biother Radiopharm. 2003a;18(2):225–30.

Breitz H, et al. Dosimetry of high dose skeletal targeted radiotherapy (STR) with ho-166-DOTMP. Cancer Biother Radiopharm. 2003b;18(2):225–30.

Breitz HB, et al. 166Ho-DOTMP radiation-absorbed dose estimation for skeletal targeted radiotherapy. J Nucl Med. 2006;47(3):534–42.

Brown RF, Lindersmith LC, Day DE. 166Ho-holmium-containing glass for internal radiotherapy of tumors. International journal of radiation applications and instrumentation. Part B. Nucl Med Biol. 1991(1);8(7):783–90.

Bult W, Koeze SQ, Elschot M, Seevinck PR, Beekman FJ, de Jong HW, Uges DR, Kostenik JG, Luijten PR, Hennink WE, van het Schip AD, Bosch JL, Nijssen JF. Intratumoral administration of holmium-166 acetylacetonate microspheres: antitumor efficacy and feasibility of multimodality imaging in renal cancer. PLoS One. 2013b(9):e52178.

Bult W, Verne MA, Vandermeulen E, Gielis I, Seevinck PR, Saunders J, van Het Schip AD, Bakker CJ, Krijger GC, Peermans K, Nijssen JF. Microbrachytherapy using holmium-166 acetylacetonate microspheres: a pilot study in a spontaneous cancer animal model. Brachytherapy. 2013a;12(2):171–7.

Bult W, et al. Nanospheres with ultrahigh holmium content for radioablation of malignancies. Pharm Res. 2009;26(6):1371–8.

Bult W, et al. Holmium nanoparticles: preparation and in vitro characterization of a new device for radioablation of solid malignancies. Pharm Res. 2010;27(10):2205–12.

Bult W, et al. Radioactive holmium acetylacetonate microspheres for interstitial microbrachytherapy: an in vitro and in vivo stability study. Res. Pharm. 2012(23(3)):827–36.

Campos TPR, et al. Study of the Sm-153 seeds degradation and evaluation of the absorbed dose in rabbit’s liver implants. Prog Nucl Energy. 2008;50(7):757–66.

Cho B-B, Choi K. Preparation of chitosan microspheres containing 166Dy/166Ho in vivo generators and their theranostic potential. J Radioanal Nucl Chem. 2018;317(2):1123–32.

Cho YJ, Kim K, Chun YS, Ryuhi K, Kwon BK, Kim DY, Yoo MC. Radiosotope synoviorthesis with Holmium-166-chitosan complex in haemophilic arthropathy. Haemophilia. 2010;16(4):640–6.

Chung YL, Lee JD, Bang D, Lee JB, Park KB, Lee MG. Treatment of Bowen’s disease with a specially designed radioactive skin patch. Eur J Nucl Med. 2000;27(7):842–6.

Costa RF, Osso Junior JA. Cation exchange resins labeled with holmium-166 for treatment of liver malignancy. Conference proceedings: DOSWIN 2008: 1 Symposium of internal dosimetry applied to nuclear medicine. Brazil. 2008.

Costa RF, et al. Production of microspheres labeled with 166Ho for liver cancer therapy: the preliminary experience at IPEN/CNEN-SP, in INAC 2009: International nuclear atlantic conference Innovations in nuclear technology for a sustainable future. Brazil. 2009.

du Silva FM, de Almeida JC, Oliveira EEM, de Souza Albernaz M, Rossi AM, Santos-Oliveira R. Nano-hydroxyapatite doped with Ho-166 as drug delivery system for bone cancer therapy and diagnosis: a developing in vivo generator system. Anticancer Agents Med Chem. 2017;17(3):355–8.

Das T, et al. Preparation and animal biodistribution of 166Ho labeled DOTA for possible use in intravascular radiation therapy (IRT). J Label Compd Radiopharm. 2003;46(3):197–209.

Das T, et al. 166Ho-labeled hydroxyapatite particles: a possible agent for liver cancer therapy. Cancer Biother Radiopharm. 2009a;24(1):7–14.

Das T, et al. Preparation of 166Ho-osine-lipiodol and its preliminary bioevaluation for the potential application in therapy of liver cancer. Nucl Med Commun. 2009b;30(5):362–7.

de Campos TP, Nogueira LB, Trindade B, Cuperschmid EM. Dosimetric intercomparison of permanent Ho-166 seed’s implants and HDR Ir-192 brachytherapy in breast cancer. Rep Pract Oncol Radiother. 2016;21(3):240–9.

Denis-Bacelar AA, et al. Bone lesion absorbed dose profiles in patients with metastatic prostate cancer treated with molecular radiotherapy. Br J Radiol. 2018;91(1084):20170795.

Di Pasqua AJ, et al. Preparation of neutron-activatable holmium nanoparticles for the treatment of ovarian cancer metastases. Small. 2012;8(7):997–1000.

Di Pasqua AJ, et al. Neutron-Activatable holmium-containing mesoporous silica nanoparticles as a potential radionuclide therapeutic agent for ovarian Cancer. J Nucl Med. 2013;54(1):111–6.

Diniz MF, Ferreira DM, de Lima WG, Pedrosa ML, Silva ME, de Almeida Araujo S, Sampaio KH, de Campos TPR, Siqueira SL. Biodegradable seeds of holmium don’t change neurological function after implant in brain of rats. Rep Pract Oncol Radiother. 2017;22(4):319–26.

Donarzon BA, Campos TP, Dalmazio J, Valente ES. Synthesis and characterization of calcium phosphate loaded with Ho-166 and Sm-153: a novel biomaterial for treatment of spine metastases. J Mater Sci Mater Med. 2013;24(2):2873–80.

Edmonds J, et al. A comparative study of the safety and efficacy of dysprosium-165 hydroxy macro-aggregate and yttrium-90 silicate colloid in radiation synoviorthectomy—a multicentre double blind clinical trial. Australian dysprosium trial group. Br J Rheumatol. 1994;33(10):947–53.

Elsholtz M, et al. Quantitative evaluation of scintillation camera imaging characteristics of isotopes used in liver radioembolization. PLoS One. 2011;6(11):e26174.

Elsholtz M, et al. (99m)Tc-MAA overestimates the absorbed dose to the lungs in radioembolization: a quantitative evaluation in patients treated with (166)Ho-microspheres. Eur J Nucl Med Mol Imaging. 2014;41(10):1965–75.

Ferro-Flores G, Hernández-Oviedo O, Arteaga de Murphy C, Tendilla Ji, Monroy-Guzman F, Pedraza-Lopez M, Aldama-Alvarado K. [166Ho]Dy/166Ho hydroxy macroaggregates: an in vivo generator system for radiation synoviorthectomy. Appl Radiat Isot. 2004;61(1):227–33.

Ferro-Flores G, et al. Labeling of biotin with [166Dy]Dy/166Ho as a stable in vivo generator system. Int J Pharm. 2003;255(1–2):129–38.
Makela O, Sukura A, Penttilä P, Hiltunen J, Tulamo RM. Radiation synovectomy with holmium-166 ferric hydroxide macroaggregate. Ann Rheum Dis. 2003b;62(1):43-48.

Huh R, et al. Therapeutic effects of Holmium-166 chitosan complex in rat brain tumor model. Jpn J Cancer Res. 2005;96(2):159-165.

Kim HS, Cho YH, Kim JS, Oh YT, Chun MS, Joh CW, Kim EH, Kim KH, Vahc YW, Jang JS, Lee BK. Measurement of radiation absorbed dose in endovascular Ho-166 brachytherapy using a balloon angio-catheter. Nucl Med Commun. 2002;23(10):959-64.

Johnson LS, Yanch JC. Absorbed dose profiles for radionuclides of frequent use in radiation synovectomy. Arthritis Rheum. 1991;34(12):1521-30.

Khorami-Moghadam A, Bolouri B, Jallilian AR, Bahrami-Samani NM, Mazidi SM, Alirezapour B. Preclinical evaluation of holmium-166 labeled anti-VEGF-Al seeded nanoparticle. J Labelled Comp Radiopharm. 2013;56(8):365-9.

Kim HS, Cho YH, Kim JS, Oh YT, Kang HJ, Chun MS, Joh CW, Park CH, Park KB, Taik SJ, Choi BW. Effects of transcatheter endovascular radiation with holmium-166 on neointimal formation after balloon injury in porcine coronary artery. J Nucl Cardiol. 2003;10(5):478-83.

Kim J, et al. In-situ formation of holmium oxide in pores of mesoporous carbon nanoparticles as substrates for neutron-activatable radiopeptide. Carbon. 2017;117:92-9.

Kim JH, Lee JT, Kim DK, Won JY, Kim MJ, Lee JD, Hong SJ. Percutaneous sclerotherapy of renal cysts with a beta-emitting radionuclide, holmium-166-chitosan complex. Korean J Radiol. 2004;5(2):128-33.

Kim JK, et al. Long-term clinical outcome of phase IIb clinical trial of percutaneous injection with holmium-166/chitosan complex (Milican) for the treatment of small hepatocellular carcinoma. Clin Cancer Res. 2006;12(2):543-8.

Kim W, Jeong MH, Park OY, Rho JK, Choi SJ, Park KB, Kim EH, Kim JH, Ahn YK, Park JT, Cho JG, Park JC, Kang JC. Effects of beta-radiation using a holmium-166 coated balloon on neointimal hyperplasia in a porcine coronary stent restenosis model. Circ J. 2003;67(7):625-9.

Kraft O, Kaspalek R, Ullmann V, Mielich F, Kropacek M, Mitrajitovova M. Radiosynoviotherapy of knee by means of 166Ho-holmium-boro-macroaggregates. Cancer Biother Radiopharm. 2007;22(2):296-302.

Kvash C, et al. Effective local control of prostate cancer by intratumoral injection of 166 ho-chitosan complex (DW-166HC) in rats. Eur J Nucl Med Mol Imaging. 2005;32(12):1400-5.

Lee JD, Park KK, Lee MG, Kim EH, Rhim KI, Lee JT, You HS, Kim YM, Park KB, Kim JR. Radionuclide therapy of skin cancers and Bowen's disease using a specially designed skin patch. J Nucl Med. 1997;38(3):697-702.

Lee JD, Yang WJ, Lee MG, Ryu YH, Park JH, Shin KH, Kim GE, Suh CO, Seong JS, Han BH, Choi CW, Kim EH, Kim KH, Park KB. Effective local control of malignant melanoma by intratumoral injection of a beta-emitting radionuclide. Eur J Nucl Med Mol Imaging. 2002;29(2):221-30.

Lee SH, Suh JS, Kim HS, Lee JD, Song J, Lee SK. MR evaluation of radiation synovectomy of the knee by means of intra-articular injection of holmium-166-chitosan complex in patients with rheumatoid arthritis: results at 4-month follow-up. Korean J Radiol. 2003;4(3):170-8.

Lee TH, Cho YH, Lee JD, Yang WJ, Shin IL, Lee MG. Enhanced antitumor effect of dendritic cell based immunotherapy after intratumoral injection of radionuclide H0-166 against B16 melanoma. Immunol Lett. 2006;106(1):19-26.

Louw WK, et al. Evaluation of samarium-153 and holmium-166-EDTMP in the normal baboon model. Nucl Med Biol. 1996;23(8):935-40.

Majali MA, et al. Potential 166Ho radiopharmaceuticals for endovascular radionuclide therapy. Il. Preparation and evaluation of 166Ho-DTPA. Nucl Med Commun. 2001;22(1):97-103.

Makela O, Pventtilp A, Kolheimainen E, Sukura A, Sankari S, Tulamo RM. Experimental radiation synovectomy in rabbit knee with holmium-166 ferric hydroxide macroaggregate. Nucl Med Biol. 2002;29(5):593-8.

Mafta O, Sukura A, Pventtilp A, Hiltunen J, Tulamo RM. Radiation synovectomy with holmium-166 ferric hydroxide macroaggregate in equine metacarpophalangeal and metatarsophalangeal joints. Vet Surg. 2003a;32(4):402-9.

Makela OT, Lammi MJ, Uusitalo H, Hyttinen MM, Vuorio E, Helminen HJ, Tulamo RM. Ann Rheum Dis. 2003b;62(1):43-9.

Makela OT, Lammi MJ, Uusitalo H, Viitanen M, Hytynen MM, Jurvelin JS, Vuorio E, Helminen HJ, Tulamo RM. Effect of radiosynovectomy with holmium-166 ferric hydroxide macroaggregate on adult equine cartilage. J Rheumatol. 2004;31(2):321-8.
Marques F, et al. 13- and 14-membered macrocyclic ligands containing methylcarboxylate or methylphosphonate pendant arms: chemical and biological evaluation of their 153Sm and 166Ho complexes as potential agents for therapy or bone pain palliation. J Inorg Biochem. 2006;100(2):270–80.

McLaren A, et al. Dysprosium (165Dy) hydroxide macroaggregates for radiation synovectomy — animal studies. Eur J Nucl Med. 1990;16(8):627–32.

Mohsin H, Ji J, Bryant JH, Siaguru G, Cutler CS, Ketring AR, Miller WH, Simon J, Frank RK, Theodore LJ, Axworthy DB, Jurisson SS, Lewis MR. Comparison of pretargeted and conventional CC49 radioimmunoconjugate using 199Pm, 166Ho, and 177Lu. J Nucl Med. 2011;52(12):2444–52.

Mohsin H, Ji J, Siaguru G, Hudson MJ, Shelton TD, Hoffman TJ, Cutler CS, Ketring AR, Athey PS, Simon J, Frank RK, Jurisson SS, Lewis MR. Radiolanthanide-labeled monoclonal antibody CC49 for radioimmunoconjugate of cancer biological comparison of DOTA conjugates and 199Pm, 166Ho, and 177Lu. J Nucl Med. 2006;47(2):485–92.

Mumper RJ, Jay MJ. Biodegrable radiotherapeutic polymer microspheres: optimization and in-vitro/in-vivo evaluation. J Control Release. 1992;18(3):193–203.

Mumper RJ, Mills BJ, Ryo YY, Jay MJ. Polymeric microspheres for radionuclide synovectomy containing neutron-activated holmium-166. J Nucl Med. 1992;33(3):398–402.

Munaweera I, Levesque-Bishop D, Shi Y, Di Pasqua AJ, Balkus KJ Jr. Radiotherapeutic bandage based on electrosyn polycrylicnitrile containing holmium-166 iron garnet nanoparticles for the treatment of skin cancer. ACS Appl Mater Interfaces. 2014;6(24):22250–6.

Munaweera I, Shi Y, Konen B, Saez R, Allev A, Di Pasqua AJ, Balkus KJ Jr. Chemoradiotherapeutic magnetic nanoparticles for targeted treatment of nonsmall cell lung cancer. Mol Pharm. 2015;12(10):3588–96.

Muzzarelli R, et al. Biological activity of chitosan: ultrastructural study. Biomaterials. 1988;9(3):247–52.

Nayak D, Lahiri S. Application of radioisotopes in the field of nuclear medicine - I. lanthanide series elements. J Radioanal Nucl Chem. 1999;242(2):423–32.

Nethaway D, Missimer M. The half-lives of 166Ho, 167Tm, 168Tm and the 165Ho (n,γ) cross-section. J Inorg Nucl Chem. 1992;54(3):15–8.

Nijman F, et al. Targeting of liver tumour in rats by selective delivery of holmium-166 loaded microspheres: a biodistribution study. Eur J Nucl Med. 2001;28(6):743–9.

Nijens JF, Krijger GC, van Het Schip AD. The bright future of radionuclides for cancer therapy. Anti Cancer Agents Med Chem. 2002a;3(4):253–66.

Nethaway D, Missimer M. The half-lives of 166Ho, 167Tm, 168Tm and the 165Ho (n,γ) cross-section. J Inorg Nucl Chem. 1992;54(3):15–8.

Nijens JF, et al. Advances in nuclear oncology: microspheres for internal radiouclide therapy of liver tumours. Curr Med Chem. 2002a(9):73–82.

Nijens JF, et al. Influence of neutron irradiation on holmium acetylacetonate loaded poly(l-lactic acid) microspheres. Biomaterials. 2002b;23(8):1831–9.

Nijens JF, et al. Liver tumors: MR imaging of radioactive holmium microspheres—phantom and rabbit study. Radiology. 2004;231(2):491–9.

Nijens JFW, et al. Holmium-166 poly lactide microspheres applicable for intra-arterial radionuclide therapy of hepatic malignancies: effects of preparation and neutron activation techniques. Eur J Nucl Med. 1999;26(7):699–704.

Nogueira LB, Campos TPR. Nuclear characterization and investigation of radioactive bioglass seed surfaces for brachytherapy via scanning electron microscopy. J Sol-Gel Sci Technol. 2011;58(1):251–8.

Nogueira LB, Campos TPR. Synthesis, chemical characterization and radiological response of ho and HoZr bioglass seeds. J Sol-Gel Sci Technol. 2016;77(3):688–98.

Nogueira LB, de Campos TP. Radiological response of ceramic and polymeric devices for breast brachytherapy. Appl Radiat Isot. 2012;70(4):663–9.

Oefellermans C, et al. Holmium-lipidol-alginate microspheres for fluoroscopy-guided embolotherapy and multimodality imaging. Int J Pharm. 2015;482(1–2):47–53.

Ofuogu S, et al. Radiation synovectomy with [166Ho-feric hydroxide: a first experience. J Nucl Med. 2002;43(11):1489–94.

Park JS, Oh JH, Kim DY, Park YK, Park SJ, Kim SJ. Effects of intraluminal irradiation with holmium-166 for TIPS stenosis: experimental study in a swine model. Korean J Radiol. 2007;8(2):127–33.

Park KB, Lu, Lambert R. Preparation of dysprosium-165/holmium-166 macroaggregate for radiation synovectomy. J Radioanal Nucl Chem. 1996;200(1):15–16.

Park S, Kang WC, Rhee JH, Ko YG, Choi D, Jang Y, Lee JD, Shim WH, Cho SY. Intracoronary 166Holmium brachytherapy combined with cutting balloon angioplasty for the treatment of in-stent restenosis. Cardiovasc Radiat Med. 2003(4):119–25.

Parks NJ, Kawakami TG, Avila MJ, White R, Cain GR, Avila MJ, White R, Cain GR, Avila MJ, White R, Cain GR, Avila MJ, White R, Cain GR, Avila MJ, White R, Cain GR. Bone marrow transplantation in dogs after radio-ablation with a new Ho-166 amino phosphonic acid bone-seeking agent (DOTMP). Blood. 1993;82(1):121–30.

Pedraza-Lopez M, et al. Preparation of [166Dy(Dy166)(DOTMP): a potential in vivo generator system for bone marrow ablation. Nucl Med Commun. 2004a;25(6):615–21.

Pedraza-Lopez M, et al. Cytotoxic and genotoxic effect of the [166Dy(Dy166)(DOTMP: in vivo generator system in mice. Nucl Med Biol. 2004b;31(8):1079–85.

Prince JF, et al. Radiation emission from patients treated with holmium-166 radioembolization. J Vasc Interv Radiol. 2014;25(12):1956–63 e1.

Prince JF, et al. Safety of a scout dose preceding hepatic Radioembolization with ho-166 microspheres. J Nucl Med. 2015;56(8):817–23.

Prince JF, et al. Efficacy of Radioembolization with [166Ho-microspheres in salvage patients with liver metastases: a phase 2 study. J Nucl Med. 2018;59(4):582–8.

Radosa CG, et al. Holmium-166 Radioembolization in hepatocellular carcinoma: feasibility and safety of a new treatment option in clinical practice. Cardiovasc Intervent Radiol. 2019;42(3):405–12.

Rajendran JG, et al. High-dose 166Ho-DOTMP in myeloablative treatment of multiple myeloma: pharmacokinetics, biodistribution, and absorbed dose estimation. J Nucl Med. 2002;43(10):1383–90.
Won JH, Lee JD, Wang HJ, Han JH, Kim KH, Park KB, Ikkin M. Effects of a holmium-166 incorporated covered stent placement in normal canine common bile ducts. J Vasc Interv Radiol. 2005;16(5):705–11.
Won JH, Lee JD, Wang HJ, Kim GE, Kim BW, Yim H, Han SK, Park CH, Joh CW, Kim KH, Park KB, Shin KM. Self-expandable covered metallic esophageal stent impregnated with beta-emitting radionuclide: an experimental study in canine esophagus. Int J Radiat Oncol Biol Phys. 2002;53(4):1005–13.
Wonderegem M, et al. 99mTc-macroaggregated albumin poorly predicts the intrahepatic distribution of 90Y resin microspheres in hepatic radioembolization. J Nucl Med. 2013;54(8):1294–301.
Yousefnia H, et al. Preliminary dosimetric evaluation of (166)ho-TTHMP for human based on biodistribution data in rats. Appl Radiat Isot. 2014;94:260–5.
Zeevaart JR, et al. Metal-ion speciation in blood plasma incorporating the tetraphosphonate, N,N-dimethylene phosphonate-1-hydroxy-4-aminopropylenediphosphonate (APDMP), in therapeutic radiopharmaceuticals. J Inorg Biochem. 2001;83(1):57–65.
Zielhuis SW, Seppenwoolde JH, Mateus VA, Bakker CJ, Krijger GC, Storm G, Zonnenberg BA, van het Schip AD, Koning GA, Nijssen JF. Lanthanide-loaded liposomes for multimodality imaging and therapy. Cancer Biother Radiopharm. 2006;21(5):520–7.
Zielhuis SW, et al. Characterization of holmium loaded alginate microspheres for multimodality imaging and therapeutic applications. J Biomed Mater Res A. 2007;82(4):892–8.
Zolghadri S, Jalilian AR, Naseri Z, Yousefnia H, Bahrami-Samani A, Ghannadi-Maragheh M, Afarideh H. Production, quality control and biological evaluation of (166)Ho-PDTMP as a possible bone palliation agent. Iran J Basic Med Sci. 2013;16(5):719–25.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.